Does Wegovy Help With Food Noise — and What Does That Actually Feel Like?

You know the feeling: it's 10am and you've already thought about dinner three times

That's food noise. Not ordinary hunger, something more like a background programme running constantly, pulling your attention back to food when you're trying to work, sleep or just get through the afternoon. Many people who carry extra weight describe it not as greed or lack of discipline but as an exhausting cognitive load that follows them everywhere.

Wegovy (semaglutide 2.4mg, made by Novo Nordisk) is a GLP-1 receptor agonist. GLP-1 is a gut hormone released after eating, and its receptors are found not only in the pancreas and stomach but in the hypothalamus and other brain regions involved in hunger signalling. When semaglutide activates those receptors, it appears to dial down the drive-to-eat signal at its source. Patients and clinicians have used the phrase "food noise" specifically because the subjective experience is often described as quiet (thoughts about food simply becoming less frequent and less urgent) rather than white-knuckling through cravings. For a thorough look at what the research and patient experience say, our guide to Wegovy and food noise goes deeper into the mechanisms.

The NHS medicines page for semaglutide describes reduced appetite as one of the treatment's recognised effects. This is the clinical underpinning for what people are reporting in experiential terms.

What the trial data actually shows about appetite and craving

The STEP 1 trial (68 weeks, adults with obesity or overweight plus a weight-related condition, semaglutide 2.4mg versus placebo alongside lifestyle changes) found an average body-weight reduction of around 15% in the semaglutide group, published in the New England Journal of Medicine. Alongside weight outcomes, participants reported significantly lower scores on appetite and craving measures. Hunger ratings, food preoccupation scores and the urge to eat all fell more markedly in the semaglutide arm than in the placebo arm.

That matters because it tells us something beyond calorie restriction: the medicine appears to reduce the psychological demand of eating less, not merely the physical capacity for it. People weren't just eating fewer calories because their stomach emptied more slowly, they were thinking about food less. If you're curious how this translates into practical eating on treatment, what to eat on Wegovy covers the dietary side in detail.

It's also worth noting that the effect isn't uniform. Some patients describe the food noise reduction as profound and almost immediate in the first couple of weeks. Others notice a more gradual change. A smaller number find the injection's effect on appetite more modest. The variable that often predicts experience is the individual, their baseline hunger physiology, their dose level, and how their body responds to semaglutide specifically. If you find yourself still feeling hungry on Wegovy, that page addresses what might be going on.

Does food noise come back, and what about between doses?

A question our prescribers hear fairly regularly: does the effect wear off between weekly injections? For most people, semaglutide's half-life means the appetite-suppressing effect is relatively consistent across the week, though some people report it feeling slightly stronger in the two or three days after the injection. Food noise creeping back can sometimes signal that a dose increase may be appropriate, which is a clinical decision made with a prescriber rather than something to act on unilaterally.

There's also the question of whether food noise returns if treatment stops. The honest answer: weight and appetite tend to return when GLP-1 medicines are discontinued, because the underlying biology reasserts itself. That's not a failure of willpower; it's how the physiology works. Treatment decisions (including how long to continue) belong in a clinical conversation. Understanding whether Wegovy stops food noise entirely, or simply reduces it, is a distinction worth exploring before starting.

For a broader look at the treatment itself, our Wegovy overview covers the licence, dose schedule, side effects and who it's suitable for. And if cost is part of your thinking, our Wegovy price comparison sets out what private treatment typically costs in the UK and what a legitimate price should include. Wegovy is a prescription-only medicine; any route to it requires proper clinical assessment.

Starting treatment: what to expect in the early weeks

Wegovy begins at 0.25mg, stepping up every four weeks through 0.5mg, 1.0mg, 1.7mg and ultimately to 2.4mg maintenance, or, since April 2026, up to 7.2mg via a dedicated single-dose pen for those who need it, following MHRA approval. The food noise effect tends to become more noticeable as the dose increases, which is one reason patients are advised not to judge the treatment on its starter doses alone.

Early side effects are mostly gastrointestinal: nausea, some stomach discomfort, changes in bowel habit. These are most common in the days after starting or increasing a dose and usually settle. Eating smaller portions of lower-fat food during that adjustment period helps. For meal ideas that work well alongside treatment, Wegovy-friendly meals is a practical starting point.

The pen itself arrives via DPD the next working day, in plain unbranded packaging, discreet by design. Each injection is once weekly, subcutaneous, in the abdomen, thigh or upper arm. For anyone considering treatment, starting a free consultation is the first step: a GPhC-registered prescriber reads your answers the same day and confirms whether treatment is clinically appropriate for you.